SCHEMBL5113515

SCHEMBL5113515

C#Cc1ccsc1-c1nc2cnccn2c1NC.c1cc2cc-2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 12/20 0.41
LMNA P02545 4/20 0.41
KDM4E B2RXH2 4/20 0.41
BRAF P15056 2/20 0.41
MAPK1 P28482 2/20 0.41
MAPT P10636 9/20 0.40
TUBB4A P04350 3/20 0.39
TUBB P07437 3/20 0.39
TUBA3C P0DPH7 3/20 0.39
TUBA1B P68363 3/20 0.39
TUBA4A P68366 3/20 0.39
TUBB4B P68371 3/20 0.39
TUBB3 Q13509 3/20 0.39
TUBB2A Q13885 3/20 0.39
TUBB8 Q3ZCM7 3/20 0.39
TUBA3E Q6PEY2 3/20 0.39
TUBA1A Q71U36 3/20 0.39
TUBA1C Q9BQE3 3/20 0.39
TUBB6 Q9BUF5 3/20 0.39
TUBB2B Q9BVA1 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118759 0.90 CDK9 (0.41) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5127406 0.90 SALL4 (0.46) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5129311 0.89 PLAU (0.42) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5114310 0.89 SYK (0.40) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5121032 0.88 CDK9 (0.41) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5128033 0.87 BRD4 (0.48) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5122857 0.86 BRD4 (0.45) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5122233 0.86 BRD4 (0.50) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5125228 0.86 GAA (0.51) GAALMNAKDM4EBRAFMAPK1
SCHEMBL5127803 0.86 SYK (0.39) GAALMNAKDM4EBRAFMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS GAA 234/4885LMNA 627/4885KDM4E 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.